127 results
Page 4 of 7
8-K
EX-99.2
1l3cu
3 Nov 22
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
7:02am
8-K
EX-99.1
cf7n5cv55gbrc
6 Sep 22
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
75tfxid8b7hth1q8vy
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
424B5
dl91 4hfaugt5q8
20 May 22
Prospectus supplement for primary offering
4:02pm
8-K
EX-10.1
zkb6bkk9c50
6 May 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.2
ilhi1nbtyrpf7sp
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.3
5ugzw 48t5
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.2
iboiy8ix7soow4
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
8-K
EX-99.1
n6etasspv
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.2
qfdr65z1 pvx
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
EX-99.1
ijutbf5
9 Sep 21
Regulation FD Disclosure
7:00am